Product Datasheet

MAX-40279 hemifumarate

Catalog No. **BP-02269** · CAS **2388506-43-0** · Form **free base** · Physical state **solid** · Color **Off-white to light yellow** · Version **1.0** · Revision **2026-09-04**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
FLT3; FGFR	**Inflammation/Immunology; Cancer**

Molecular formula	$C_{48}H_{50}F_2N_{12}O_6S_2$
Molecular weight	**993.1140**

STRUCTURE



DESCRIPTION

MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemifumarate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).

BIOLOGICAL ACTIVITY

MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase.

SOLUBILITY

Soluble in DMF

In vitro	DMF : 1.96 mg/mL

REFERENCES

[1]. Yuguang Wang, et al. Novel Therapeutic Methods. Patent WO2021180032A1.

[2]. Yuguang Wang, et al. Preclinical Evaluation of MAX-40279, a FLT3/FGFR Dual Kinase Inhibitor for Treatment of Acute Myeloid Leukemia, Blood, Volume 132, Supplement 1, 2018.

[3]. Xue Z, et al. PIM1 instigates endothelial-to-mesenchymal transition to aggravate atherosclerosis. Theranostics. 2025 Jan 1;15(2):745-765.